Transgene is developing a new generation of oncolytic viral immunotherapies that are armed with cancer-fighting genes, seeking to provide enhanced efficacy to cancer patients while reducing toxicity. At the AACR meeting, Transgene reported pre-clinical results with three oncolytic vaccinia viruses, each containing a different form of a PD-1 blocker (VV-PD-1): a full monoclonal antibody (mAb), an antigen-binding fragment (Fab) or a single-chain variable fragment (scFv). Immune checkpoint inhibitors targeting PD-1 represent a major advance in treating several forms of cancer. The data showed that all three versions of the VV-PD-1 expression products displayed (i) a perfect biochemical integrity and folding, (ii) were fully functional, and (iii) had equivalent biological activity to the corresponding anti PD-1 reference mAb. Furthermore, the biodistribution profile obtained for VV-PD-1 demonstrated a higher concentration and prolonged action of the anti PD-1 in the tumor, resulting in an improved tumor/serum ratio.
Si le fichier PDF ne s'affiche pas ou pour le télécharger, cliquez ici.
Pour consulter le fichier PDF en intégralité, cliquez ici.
|TRANSGENE||Euronext Paris||3.1250 (c)||-2.04%||47 635|